Skip to main content
Premium Trial:

Request an Annual Quote

IntelligentMDx Developing Assays for Qiagen's QIAsymphony RGQ

NEW YORK (GenomeWeb News) – IntelligentMDx said today that it has entered into a development and licensing agreement to design, develop, and manufacture CE-marked and US Food and Drug Administration-cleared diagnostic tests for use on Qiagen's QIAsymphony RGQ platform.

IMDx did not disclose the assays, but said they will be incorporated into Qiagen's growing portfolio of molecular diagnostic assays and be distributed worldwide by Qiagen. Qiagen also retained the rights to manufacture the assays pursuant to volume considerations, IMDx said.

Further financial and other terms of the multi-year deal were not disclosed.

"This collaboration will help us to accelerate the expansion of our test menu for the QIAsymphony RGQ," Dirk Zimmermann, vice president and head of development Molecular Diagnostics Europe and Asia for Qiagen, said in a statement. The deal with IMDx "helps us to maximize the value of QIAsymphony RGQ for our customers by giving them the opportunity to consolidate an expanding range of molecular tests on one system."

Based in Cambridge, Mass., IntelligentMDx develops molecular tests based on a proprietary bioinformatics platform that "allows for efficient design of robust and accurate diagnostics that can be formatted for a variety of real-time PCR platforms," the company said.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.